Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2017

Open Access 01-12-2017 | Research article

No association between the progesterone receptor gene polymorphism (+331G/a) and the risk of breast cancer: an updated meta-analysis

Authors: Xing-ling Qi, Jun Yao, Yong Zhang

Published in: BMC Medical Genetics | Issue 1/2017

Login to get access

Abstract

Background

Many published studies have estimated the association between the +331G/A (rs10895068) polymorphism in the progesterone receptor (PgR) gene and breast cancer risk. However, the results remain inconsistent and controversial. To address this inconsistency, we systematically interrogated the aforementioned association via a meta-analysis.

Methods

Through a literature search, we identified 13 case-control studies, including 12,453 cases and 14,056 case-free controls. The strengths of reported associations were evaluated using odds ratios (ORs) with 95% confidence intervals (95%CIs).

Results

An association was found between +331G/A polymorphism and +331G/A risk in the dominant model (p = 0.027). Via subgroup analysis, we found no association between +331G/A and breast cancer risk in Caucasians, Asians or mixed racial groups.

Conclusions

Through meta-analysis, we were able to gain insight into previously reported associations between +331G/A polymorphism and breast cancer risk. However, further studies are still needed to provide more evidence.
Literature
1.
Dumitrescu RG, Cotarla I. Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med. 2005;9(1):208–21.CrossRefPubMed
2.
O'Brien JM. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hemminki. N Engl J Med 343:78-84, 2000. Survey of ophthalmology. 2000;45(2):167–8.CrossRefPubMed
3.
Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11(2):266–301.CrossRefPubMed
4.
Romano A, Delvoux B, Fischer DC, Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol. 2007;38(1–2):331–50.CrossRefPubMed
5.
Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJ, Neoptolemos JP, et al. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer. 1994;30A(1):5–11.CrossRefPubMed
6.
Alghanem AA, Hussain S. The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer. J Surg Oncol. 1986;31(3):218–21.CrossRefPubMed
7.
Silva JS, Cox CE, Wells SA Jr, Paull D, Dilley WG, McCarty KS Sr, Fetter BF, Glaubitz LC, McCarty KS Jr. Biochemical correlates of morphologic differentiation in human breast cancer. Surgery. 1982;92(3):443–9.PubMed
8.
Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjold B. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. The south-East Sweden breast cancer group. Int J Cancer. 1992;51(1):28–33.CrossRefPubMed
9.
Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer. 1999;79(9–10):1564–71.CrossRefPubMedPubMedCentral
10.
Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors a and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72(2):163–72.CrossRefPubMed
11.
Rousseau-Merck MF, Misrahi M, Loosfelt H, Milgrom E, Berger R. Localization of the human progesterone receptor gene to chromosome 11q22-q23. Hum Genet. 1987;77(3):280–2.CrossRefPubMed
12.
Johnatty SE, Spurdle AB, Beesley J, Chen X, Hopper JL, Duffy DL, Chenevix-Trench G. Kathleen Cuningham consortium for research in familial breast C: progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. Breast Cancer Res Treat. 2008;109(1):91–9.CrossRefPubMed
13.
Fabjani G, Tong D, Czerwenka K, Schuster E, Speiser P, Leodolter S, Zeillinger R. Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women. Breast Cancer Res Treat. 2002;72(2):131–7.CrossRefPubMed
14.
Feigelson HS, Rodriguez C, Jacobs EJ, Diver WR, Thun MJ, Calle EE. No association between the progesterone receptor gene +331G/a polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(6):1084–5.PubMed
15.
Gabriel CA, Mitra N, Demichele A, Rebbeck T. Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women. Breast Cancer Res Treat. 2013;139(3):833–43.CrossRefPubMed
16.
De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 2003;63(17):5236–8.PubMed
17.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. W264CrossRefPubMed
18.
Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, Thompson J, Hall I, Kaufman J, Leung TF, et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005;162(3):201–11.CrossRefPubMed
19.
Yao J, Pan YQ, Ding M, Pang H, Wang BJ. Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis. Am J Med Genet Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatr Genet. 2015;168B(1):1–13.
20.
Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends in genetics : TIG. 2004;20(9):439–44.CrossRefPubMed
21.
Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291–306.CrossRefPubMed
22.
Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT, Wang HP, Lin JT. Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis. 2002;185(1):106–9.
23.
24.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed
25.
Kotsopoulos J, Tworoger SS, De Vivo I, Hankinson SE, Hunter DJ, Willett WC, Chen WY. +331G/a variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer. Int J Cancer. 2009;125(7):1685–91.CrossRefPubMedPubMedCentral
26.
Romano A, Lindsey PJ, Fischer DC, Delvoux B, Paulussen AD, Janssen RG, Kieback DG. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/a and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol. 2006;101(2):287–95.CrossRefPubMed
27.
Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, West J, Jordan C, Easton DF, Ponder BA, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev. 2006;15(4):675–82.CrossRefPubMed
28.
Jin YL, Shen YP, Chen ea JL. A case-control study on the associations of ER codon 325 and PR +331G/a with the risk of breast cancer. Tumor. 2008;28(10):859–63.
29.
Fernandez LP, Milne RL, Barroso E, Cuadros M, Arias JI, Ruibal A, Benitez J, Ribas G. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer. 2006;119(2):467–71.CrossRefPubMed
30.
al ARMBHMe. Impact of two functional progesterone receptor polymorphisms (PRP): +331G/a and PROGINS on the cancer risks in familial breast/ovarian cancer. The Open Cancer Journal. 2007;1:1–8.CrossRef
31.
Reding KW, Li CI, Weiss NS, Chen C, Carlson CS, Duggan D, Thummel KE, Daling JR, Malone KE. Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk. Am J Epidemiol. 2009;170(10):1241–9.CrossRefPubMedPubMedCentral
32.
Huggins GS, Wong JY, Hankinson SE, De Vivo I. GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/a polymorphism. Cancer Res. 2006;66(3):1384–90.CrossRefPubMed
33.
Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, Defreese DC, Gramling BA, Evans I, White E. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1751–9.CrossRefPubMedPubMedCentral
34.
Yang DS, Sung HJ, Woo OH, Park KH, Woo SU, Kim AR, Lee ES, Lee JB, Kim YH, Kim JS, et al. Association of a progesterone receptor gene +331 G/a polymorphism with breast cancer risk: a meta-analysis. Cancer Genet Cytogenet. 2010;196(2):194–7.CrossRefPubMed
35.
KD Y, Chen AX, Shao ZM. No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis. Breast Cancer Res Treat. 2010;122(3):853–8.CrossRef
36.
Chaudhary S, Panda AK, Mishra DR, Mishra SK. Association of +331G/a PgR polymorphism with susceptibility to female reproductive cancer: evidence from a meta-analysis. PLoS One. 2013;8(1):e53308.CrossRefPubMedPubMedCentral
Metadata
Title
No association between the progesterone receptor gene polymorphism (+331G/a) and the risk of breast cancer: an updated meta-analysis
Authors
Xing-ling Qi
Jun Yao
Yong Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2017
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-017-0487-3

Other articles of this Issue 1/2017

BMC Medical Genetics 1/2017 Go to the issue

Research article

Exome sequencing identified rare variants in genes HSPG2 and ATP2B4 in a family segregating developmental dysplasia of the hip

Research article

Genetic variation of the Toll-like receptors in a Swedish allergic rhinitis case population

Case report

Case reports of two pedigrees with recessive arrhythmogenic right ventricular cardiomyopathy associated with homozygous Thr335Ala variant in DSG2

Research article

PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population

Research article

Genetic characterization of Italian patients with Bardet-Biedl syndrome and correlation to ocular, renal and audio-vestibular phenotype: identification of eleven novel pathogenic sequence variants

Case report

Pulmonary manifestations in Niemann-Pick type C disease with mutations in NPC2 gene: case report and review of literature